Bromide

Bromide

SCHEMBL4440425

Br.Br.N#Cc1ccc(Sc2ccc(Cl)cc2CSC(=N)N)c(COC(=S)NN)c1

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC6A4 known ✓ P31645 3/20 0.32
SLC6A3 known ✓ Q01959 2/20 0.32
SLC6A2 known ✓ P23975 1/20 0.30
IDO1 P14902 10/20 0.41
HTT P42858 4/20 0.41
CYP1A2 P05177 2/20 0.34
PRMT1 Q99873 1/20 0.34
KCNH2 Q12809 1/20 0.32
LMNA P02545 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
TAAR1 Q96RJ0 2/20 0.32
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
HPGD P15428 1/20 0.31
ALOX15 P16050 1/20 0.31
ALDH3A1 P30838 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3680875 0.99 IDO1 (0.40) IDO1HTTCYP1A2PRMT1SLC6A4
Bromide SCHEMBL4440423 0.87 IDO1 (0.53) IDO1HTTCYP1A2PRMT1SLC6A4
SCHEMBL3680873 0.86 IDO1 (0.52) IDO1HTTCYP1A2PRMT1SLC6A4
SCHEMBL3681107 0.79 IDO1 (0.47) IDO1HTTCYP1A2PRMT1SLC6A4
Bromide SCHEMBL4437970 0.77 IDO1 (0.67) IDO1HTTCYP1A2PRMT1LMNA
SCHEMBL3752992 0.75 IDO1 (0.66) IDO1HTTCYP1A2PRMT1LMNA
Bromide SCHEMBL4436449 0.75 IDO1 (0.44) IDO1HTTCYP1A2PRMT1SLC6A4
SCHEMBL3687331 0.73 IDO1 (0.43) IDO1HTTCYP1A2PRMT1SLC6A4
SCHEMBL3687316 0.72 IDO1 (0.35) IDO1HTT
Bromide SCHEMBL4437159 0.72 IDO1 (0.46) IDO1HTTCYP1A2PRMT1SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2061754-A1 BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2009-05-27 EP disclosed
WO-2008115999-A1 BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2008-09-25 WO disclosed
US-20080234384-A1 BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234384-A1 BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS FECH, SLC10A1, SLC40A1 SLC6A4 724/4885SLC6A3 233/4885SLC6A2 247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.